Yuan Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5066957/publications.pdf

Version: 2024-02-01

27 2,031 18
papers citations h-index

18 28
n-index g-index

28 28 all docs docs citations

28 times ranked 3961 citing authors

#	Article	IF	CITATIONS
1	Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium. ACS Omega, 2019, 4, 2472-2481.	3.5	16
2	Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. Cell Chemical Biology, 2019, 26, 278-288.e6.	5.2	36
3	Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1α (HIF1α) in Cells. Biochemistry, 2018, 57, 1807-1813.	2.5	23
4	Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nature Cell Biology, 2018, 20, 597-609.	10.3	306
5	Sumoylation of RORÎ ³ t regulates TH17 differentiation and thymocyte development. Nature Communications, 2018, 9, 4870.	12.8	22
6	Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme. Nature Communications, 2018, 9, 5145.	12.8	46
7	The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. Clinical Cancer Research, 2018, 24, 6053-6065.	7.0	27
8	SUMO-mediated regulation of NLRP3 modulates inflammasome activity. Nature Communications, 2018, 9, 3001.	12.8	134
9	Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2018, 138, 2377-2387.	0.7	16
10	Regulation of miR-34b/c-targeted gene expression program by SUMOylation. Nucleic Acids Research, 2018, 46, 7108-7123.	14.5	16
11	Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nature Communications, 2017, 8, 2099.	12.8	45
12	Domain alternation and active site remodeling are conserved structural features of ubiquitin E1. Journal of Biological Chemistry, 2017, 292, 12089-12099.	3.4	22
13	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. Oncotarget, 2017, 8, 79750-79760.	1.8	12
14	MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. Anticancer Research, 2017, 37, 2831-2838.	1.1	11
15	Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. Nature Communications, 2016, 7, 12326.	12.8	78
16	Observation of an E2 (Ubc9)-homodimer by crystallography. Data in Brief, 2016, 7, 195-200.	1.0	2
17	Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation. Journal of Molecular Biology, 2016, 428, 579-589.	4.2	24
18	Hydroxamic Acid and Benzoic Acid–Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes <i>In Vitro</i> and <i>In Vivo</i> Cancer Research, 2016, 76, 652-663.	0.9	66

Yuan Chen

#	Article	IF	CITATION
19	HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breast cancer tumorigenicity. Oncotarget, 2016, 7, 34052-34069.	1.8	21
20	Breast-cancer-secreted miR-122 reprograms glucoseÂmetabolism in premetastatic niche toÂpromoteÂmetastasis. Nature Cell Biology, 2015, 17, 183-194.	10.3	895
21	Design of High-Throughput Screening Assays and Identification of a SUMO1-Specific Small Molecule Chemotype Targeting the SUMO-Interacting Motif-Binding Surface. ACS Combinatorial Science, 2015, 17, 239-246.	3.8	5
22	Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma. Journal of Medicinal Chemistry, 2015, 58, 7734-7748.	6.4	22
23	Conformational flexibility and changes underlying activation of the SUMO-specific protease SENP1 by remote substrate binding. Nature Communications, 2014, 5, 4968.	12.8	15
24	Impaired p32 Regulation Caused by the Lymphoma-Prone RECQ4 Mutation Drives Mitochondrial Dysfunction. Cell Reports, 2014, 7, 848-858.	6.4	28
25	Identification and Characterization of a New Chemotype of Noncovalent SENP Inhibitors. ACS Chemical Biology, 2013, 8, 1435-1441.	3.4	38
26	Mechanism of E1-E2 Interaction for the Inhibition of Ubl Adenylation. Journal of Biological Chemistry, 2010, 285, 33457-33462.	3.4	15
27	Role of an N-Terminal Site of Ubc9 in SUMO-1, -2, and -3 Binding and Conjugationâ€. Biochemistry, 2003, 42, 9959-9969.	2.5	89